全国垂询热线
020-84128820


新闻资讯

联系我们

广州市雨纯生物科技有限公司
全国垂询热线:020-84128820
传真:020-84128836
地址:广州市增城中新镇福和坪中南路151号

Good prospects for good health development, domestic pharmaceutical companies have set foot in
专栏:Industry News
发布日期:2015-09-29
阅读量:1901
作者:佚名
收藏:
[China Pharmaceutical Network Industry News] The relevant data pointed out that the potential of the big health market is unlimited. In 2020, the global output value of the health industry will ...

      [China Pharmaceutical Network Industry News] The relevant data pointed out that the potential of the big health market is unlimited. In 2020, the global output value of the health industry will reach 13.39 trillion US dollars. Many traditional pharmaceutical companies in China have begun to increase this area, intending to win a piece of cake. . Good prospects for good health development, domestic pharmaceutical companies have set foot in

Domestic big health industry structure imbalance

       According to relevant data, in 2020, the global output value of the health industry will reach 13.39 trillion US dollars, and the global per capita health expenditure will continue to grow rapidly, reaching 1882.188 US dollars by 2020.

       On September 23, Li Jinhua, vice president of Guangzhou Pharmaceutical Research Institute of Guangzhou Pharmaceutical Group, held the press conference of the China Plant Extract Industry International Competitiveness Enhancement Forum held by the Planting Bridge Media, on the current development of the big health industry. The analysis. He believes that the new round of growth is mainly due to the population growth in low- and middle-income countries and middle- and high-income countries, and the sustained release of per capita health demand, while the advancement of technology has brought a new round of industrial upgrading, which is the health industry of developed countries. Development brings new growth drivers.

       According to the relevant economic research data of the US Department of Commerce, the US health industry is the fifth largest industry after manufacturing, service, finance, and real estate, and the fastest growing industry in the past decade, accounting for the proportion of GDP. 8.8% Li Jinhua also believes that compared with the United States, China's large health industry is still in its infancy, and needs to be upgraded and improved in terms of industry segmentation and structural rationalization. As the concept of big health continues to heat up, the development of this industry has also begun to enter the fast lane. Many traditional pharmaceutical companies in the country have begun to add to this field, intending to win a piece of cake.

Pharmaceutical companies also come to "play games"

       As the concept of big health continues to heat up, the development of this industry has also begun to enter the fast lane. Many traditional pharmaceutical companies in the country have begun to add to this field, intending to win a piece of cake.

       Li Jinhua believes that compared with the small profit margin of pharmaceuticals, the increase of production costs, the difficulty in research and development of new drugs, high investment, and stricter industry supervision, the entry barriers for large health industries are lower, which is more attractive to pharmaceutical companies. At the same time, with the continuous segmentation of the big health market, pharmaceutical companies will be divided into four major types in the future.

Four types

       At present, a group of pharmaceutical companies with the ability to have visions have entered the health industry, greatly improving the R&D, production and marketing capabilities of China's health industry and becoming a new force in China's health industry in the future. Domestic pharmaceutical companies involved in the big health industry (parts)

       However, Li Jinhua also pointed out that traditional pharmaceutical companies entering the big health product market have much higher requirements for corporate management and market operation than the current status of traditional pharmaceutical companies, and more like a highly demanding "game." Health care products industry 100-1=0? The big health industry is divided into four major areas: the medical field, the pharmaceutical industry, the health care product industry, and health services. As an important pole in the big health industry, health care products have become the first choice for many companies. According to CFDA data, as of the end of 2014, there were 2,587 national health care products companies. In 2013, the annual output value of national health food production enterprises was nearly 300 billion yuan.

       On the other hand, as of the end of 2014, there were 5,000 pharmaceutical companies in the country. According to Zhongkang CMH data, in 2014, the total size of the entire Chinese pharmaceutical market (excluding medicinal materials) reached RMB 128.2 billion (according to retail prices). 2015 China Plant Extract Industry International Competitiveness Enhancement Forum Guangzhou Station Press Conference, Deputy General Manager of Tomson Bianjian Co., Ltd. and General Manager of Zhuhai Base Cai Liangping analyzed that in terms of quantity, health products are not far from pharmaceutical companies. However, the market size is quite different. From the perspective of consumption patterns of medicines and health products, it should be that the market for health products is larger, but the reality is not.

Drug and health product consumption patterns

       Under normal circumstances, 100-1=99, but Cai Liangping believes that the health care products industry is 100-1=0, the missing “1” is the industry trust problem. For companies entering the field of health care products, who will solve the problem of trust, who will be able to own the market. Cai Liangping introduced that Tomson has established a transparent factory, a global raw material traceability system, a high-definition real-time live broadcast system, and an all-weather transparent factory visit. At the same time, we adhere to the five core pillars of quality brands such as global high-quality raw materials, global advanced equipment, quality management of pharmaceuticals, continuous innovation in technology research and development, and excellence in professional talents. On this basis, consumers are increasingly increasing their trust in Tomson's products.

       With the development of the Internet, information has become more and more symmetrical. With the constant consumption power, consumers are beginning to pursue a higher quality of life. The concept of health has been steadily strengthened, and people have become wary of over-medication and are moving toward disease prevention. Cai Liangping believes that China's consumption of health products will enter a new era of rational and professional consumption.

       More rational consumers are also placing higher demands on the production of health products. In the past, due to improper publicity, such as “convergence” and “indiscriminateization”, consumers lost trust in health products. In order to regain a firm foothold and truly serve the consumers, health care products companies must return to the function itself, segment the health care products for different groups of people, different time periods, etc., step out of the differentiated road, use high technology to continuously innovate and produce high quality products. .

       From the development of “pain and happiness” in the health care products industry, more or less can be seen in the development of the big health industry.

Future trends in the big health industry

       Under the factors of expanding market demand, favorable policies, and promotion from all walks of life, China's large-scale health industry has developed rapidly. In 2013, its scale was close to 2 trillion yuan. It is expected to reach 3 trillion yuan by the end of 2016, ranking first in the world.

       At present, the aging population, sub-health status and climate change have created a broad space for the development of a large health industry, and the development of science and technology provides an inexhaustible motive force for the development of health industry. High-tech, globalization, high efficiency, and front-end is national health. The future direction of the industry.

       Li Jinhua believes that in the future, the big health industry will be built on the development direction of “brand, culture and innovative products”. Traditional pharmaceutical enterprises must give full play to their advantages in brand, culture, R&D and production in entering the big health industry. Improve the business strength and influence of the company, and in the development of healthy products, we must grasp the various requirements of high safety, good curative effect, and adapt to the people's self-care, and at the same time need flexible and changeable forms.

       At the same time, as the industrial structure adjustment and competition of the big health industry intensify, the traditional marketing model is challenged, and the strategic role of the differentiated strategy formed by technological innovation in improving product quality, supporting brand development, and promoting industrial transformation and upgrading must be obtained. Highlight and strengthen.

       For enterprises that have entered or will enter the big health industry, it is necessary to have a clearer understanding of the current situation of the big health industry, solve the pain point problem, master the rules, seize the opportunity, and take the right direction to be able to refine this high-end "game". Big winner. (Source: Xinkangjie Author: Huang Xueli)

上一页:Deep perspective: regional characteristics of the three industrial clusters of medical equipment
下一页:Sino-US medical e-commerce PK: Who can compare international giants?

在线客服

在线客服
联系方式

全国热线:020-84128820